Ashton Thomas Private Wealth’s Protalix BioTherapeutics PLX Stock Holding History

Ashton Thomas Private Wealth’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$43.7K	Buy	+15,828	New	+$39.4K	﹤0.01%	1436

Other funds holding PLX

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

OGF

Orin Green Financial San Diego, California $267M AUM 12.91% 1-Year Est. Return

Kestra Advisory Services Austin, Texas $35.1B AUM 20.13% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Ashton Thomas Private Wealth's PLX Position: Q3 2026 in Review

Ashton Thomas Private Wealth opened a new position in Protalix BioTherapeutics (PLX) in Q3 2026: 15,828 shares worth $43.7K. The stake represents ﹤0.01% of the portfolio and ranks #1436 among its holdings.

23 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

Ashton Thomas Private Wealth held 15,828 shares of Protalix BioTherapeutics worth $43.7K as of Q3 2026.
Protalix BioTherapeutics was a new Ashton Thomas Private Wealth position in Q3 2026.
Protalix BioTherapeutics made up ﹤0.01% of Ashton Thomas Private Wealth's portfolio in Q3 2026, its #1436 holding.
23 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q3 2026, filed 3 Nov 2026.